Posted by Michael Wonder on 20 Sep 2022
Junshi Biosciences receives NMPA approval of sNDA for toripalimab in combination with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
20 September 2022 - Sixth approved indication of toripalimab in China, bringing more treatment options to patients with advanced non-small-cell lung cancer.
Shanghai Junshi Biosciences announced today that the China National Medical Products Administration has approved the supplemental new drug application for toripalimab in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation negative and ALK mutation negative, unresectable, locally advanced or metastatic non-squamous non-small-cell lung cancer.
